Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.33) by 89.39 percent. This is a 86.54 percent increase over losses of $(0.26) per share from the same period last year.
Related Posts
Chart Industries Q4 Adj EPS $1.67 Misses $1.70 Estimate, Sales $441.40M Miss $492.41M Estimate
Chart Industries (NYSE:GTLS) reported quarterly adjusted earnings of $1.67 per share which missed the analyst consensus estimate of $1.70 by 1.76 percent. This is a 128.77 percent increase over earnings of $0.73 per
Leidos Holdings Q3 Adj. EPS $1.80 Beats $1.62 Estimate, Sales $3.48B Miss $3.60B Estimate
Leidos Holdings (NYSE:LDOS) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.62 by 11.11 percent. This is a 22.45 percent increase over earnings of $1.47 per share from the
Booz Allen Hamilton’s Return On Capital Employed Overview
Pulled from Benzinga Pro data, Booz Allen Hamilton (NYSE:BAH) showed a loss in earnings since Q3, totaling $90.80 million. Sales, on the other hand, increased by 10.19% to $2.24 billion during Q4.